Innovative Health Information Technology for
Broad Adoption by Healthcare Systems and Consumers
Upcoming Receipt Date: August 5, 2012
The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program has announced a new funding opportunity, aimed at accelerating the development and commercialization of consumer health information technology products that translate the behavioral and communication science evidence base for the prevention and control of cancer and other chronic diseases. With up to $1.5M per Phase I/II grant, this new Program Announcement encourages small businesses to apply for funding that will further develop products to benefit consumers, patients, caregivers, and health care providers.
The NCI and their co-funding partner, the National Library of Medicine, are interested in supporting the growth and dissemination of evidence-based health information technology products that validate user-centric research outcomes and have the potential to:
- Prevent or reduce the risk of cancer
- Facilitate patient-provider communication and/or
- Improve disease outcomes in consumer and clinical settings
To view the full Program Announcement, please visit:
PA-12-196, Innovative Health Information Technology for Broad Adoption by Healthcare Systems and Consumers (SBIR) (R44)
Receipt Dates: August 5, 2012; December 5, 2012
A non-exclusive list of product examples relevant to this funding opportunity are available at: http://sbir.cancer.gov/resource/hit/.
- Applicants who have already received Phase I SBIR funding applicable to this Program Announcement may submit a Phase II; others may submit a Fast-Track application.
- Please note, applicants are strongly advised to establish a partnership with large businesses (e.g. commercial IT firms, EMR vendors, healthcare systems/payers, pharma, healthcare organizations, etc.)before the application is submitted.
- This FOA is expected to promote partnerships between SBC’s and large businesses or health-related organizations with the capacity to fully commercialize and disseminate the product. Consistent with the goals of the SBIR funding initiatives, Phase II and Fast-Track SBIR applicants must submit a Commercialization Plan, which should include details on the commercialization and dissemination of the proposed product.
- Partners in this PA will be asked to sign a legal document, before the grant commences, that addresses intellectual property and profit sharing. To view a sample SBIR partnership IP agreement, please click here.
- Applicants who adhere to these requests will receive competitive preference and funding priority.
For more information about this program announcement and details on how to apply, please click here.
For a complete list of funding opportunities from the NCI SBIR & STTR Programs, please visit: http://sbir.cancer.gov/funding/receipt_dates.asp.
The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.